MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 61

2011-2013

Department of Medicine

61

Hematology/medical
oncology Cont.

Study of DOcetasel and Ramucirumab

Novella Clinical, $1,632, 09/01/2012

versus Docetaxel and Placebo in the

to 08/31/2015

Subjects With Relapsed or Refractory

Cell Lunch Cancer Following Disease

Co-Investigator

CD22-Positive Aggressive Non-

Progression after One Prior Platinum

Adult Hemoglobinopathy Sickle

Hodgkin, Pfizer, $7,881, 03/03/2010

Based Therapy, Eli Lilly and Company,

Cell